



## Imugene announces important progress in relation to its Linguet™ Ibuprofen formulation

---

**Melbourne, 2 July 2013:** Australian drug development and pharmaceutical company Imugene (ASX.IMU) has signed an agreement with ASX-listed manufacturer IDT Australia Ltd to assist with formulation and manufacture of its Linguet fast melt ibuprofen tablets following commercial interest.

“We are very pleased to be working with IDT, a strong local manufacturing company under the exceptional leadership of Paul MacLeman and the IDT board,” said Dr Ede. “Identifying and locking in manufacturing and supply is an important milestone in de-risking the development of a pharmaceutical asset. We are following a rigorous process for mitigating risk in creating value for an identified licensee”, he added.

“IDT Australia is delighted to be working with Imugene Limited and the Linguet technology.” said Dr Paul MacLeman, IDT’s chief executive officer. “Imugene’s Ibuprofen project work fits in nicely with IDT’s strategy to generate new technology and value with industry partners.”

Imugene is developing a 200mg ibuprofen tablet which melts in the mouth and so is easier to swallow. The novel formulation, which utilises the Company’s Linguet™ technology, is designed to address issues of unpleasant taste, mouth feel and swallowing difficulties associated with non-steroidal anti-inflammatory drugs (NSAIDs).

Linguet supports “buccal” administration of drugs straight to the blood stream via absorption through the lining of the mouth; however a fast melt Ibuprofen would involve a unique application of this technology, with the result being akin to a swallowed tablet.

“The required dosing size of an ibuprofen tablet would render even a buccal tablet impractical. Hence, we are utilising our knowledge base around Linguet to create a rapid melt-in-the-mouth formulation that will assist patients who have difficulty swallowing large capsules and tablets,” Dr Ede said.

“Linguet fast melt 200mg ibuprofen tablets will be formulated to dissolve in the mouth and can then be swallowed, with the goal being there is no burning from acidic ibuprofen and no throat catch.”

For more information please visit [www.imugene.com](http://www.imugene.com).

**Ends**

**Investor contact:**

**Dr Nick Ede, Imugene** – 0400 642 254 / [nede@imugene.com](mailto:nede@imugene.com)

**Media contact:**

**Shevaun Cooper, Buchan Consulting** – 03 9866 4722 / [scooper@buchanwe.com.au](mailto:scooper@buchanwe.com.au)

**About Imugene**

Imugene Limited (ASX:IMU) is commercialising drug delivery applications based on its novel buccal (drugs administered via the cheek) Linguet™ technology. Linguet™ is a patient friendly and cost effective system used to deliver established pharmaceutical and nutraceutical products.

**About Dysphagia**

Difficulty in swallowing, also known as dysphagia, is a common problem that can affect people of any age. It is particularly prominent in older people, or those suffering diseases linked to dysphagia such as cancer and Alzheimer's disease.

In a recent UK pilot study conducted in patients aged over 65, it was found that 62% of people had difficulty in swallowing solid dose medication, and 58% had crushed tablets or opened capsules to aid administration<sup>1</sup>.

Linguet™ offers opportunities to address the issues of dysphagia. As healthcare providers are looking to reduce costs, the issue of patient compliance is becoming ever more important. Such healthcare providers are trying to reduce the length of stay and treatment within the secondary care market, pushing patients out from hospital and back into the community. As there is less supervision in the community for medicines management and monitoring of patient compliance, the requirement for more accessible ways to improve compliance will become increasingly important.

1. Strachan, I. and Greener, M. *Pharmacy in Practice* 2005;**15**: 411–414